Non-Major Bleeding Less Frequent With Apixaban

ACC Conference Reporter

ESC 2015 | LONDON — Non-major clinically relevant bleeding events occur more frequently with warfarin than with apixaban (Eliquis) in the ARISTOTLE trial, and carry an increased mortality risk to patients being treated with anticoagulants to prevent strokes caused by atrial fibrillation, researchers reported here. Read More >>>

Keywords: ESC Congress

< Back to Listings